U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 867

1.
Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast carcinogenesis
Li-Bo Cao, Zi-Lun Ruan, Yu-Lin Yang, Nian-Chao Zhang, Chuan Gao, Cheguo Cai, Jing Zhang, Ming-Ming Hu, Hong-Bing Shu
J Mol Cell Biol. 2023 Jul; 15(7): mjad047. Published online 2023 Jul 13. doi: 10.1093/jmcb/mjad047
PMCID:
PMC11066933
AbstractArticlePDF–2.0M
2.
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis
Antoine Vasseur, Luc Cabel, Caroline Hego, Wissam Takka, Olfa Trabelsi Grati, Benjamin Renouf, Florence Lerebours, Delphine Loirat, Etienne Brain, Paul Cottu, Marie-Paule Sablin, Jean-Yves Pierga, Céline Callens, Shufang Renault, François-Clément Bidard
Oncogene. 2024; 43(16): 1214–1222. Published online 2024 Feb 27. doi: 10.1038/s41388-024-02986-6
PMCID:
PMC11014798
AbstractArticlePDF–1.8M
3.
Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review
Nengying Zhang, Chengmin Luo, Jiayang Li, Yuxiang Bao, Zhongliang Yan, Xiaoming Cheng, Taolang Li, Junyuan Lv
Front Endocrinol (Lausanne) 2024; 15: 1362725. Published online 2024 Mar 13. doi: 10.3389/fendo.2024.1362725
PMCID:
PMC10976348
AbstractArticlePDF–3.1M
4.
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
Stephanie H. Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle, Francois-Clement Bidard
Breast Cancer Res Treat. 2024; 204(3): 579–588. Published online 2024 Jan 11. doi: 10.1007/s10549-023-07201-w
PMCID:
PMC10959771
AbstractArticlePDF–1.1M
5.
Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer
Li Zhi, Chen Cheng, Luo Jing, Peng Zhi-Ping, Yang Lu, Tian Yan, Wang Zhi-Gang, Yin Guo-Bing
J Nanobiotechnology. 2024; 22: 107. Published online 2024 Mar 12. doi: 10.1186/s12951-024-02309-7
PMCID:
PMC10929118
AbstractArticlePDF–3.2M
6.
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer
Jordi Rodón, David Demanse, Hope S. Rugo, Howard A. Burris, Rafael Simó, Azeez Farooki, Melissa F. Wellons, Fabrice André, Huilin Hu, Dragica Vuina, Cornelia Quadt, Dejan Juric
Breast Cancer Res. 2024; 26: 36. Published online 2024 Mar 4. doi: 10.1186/s13058-024-01773-1
PMCID:
PMC10913434
AbstractArticlePDF–2.1M
7.
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial
Eriko Tokunaga, Yasuo Miyoshi, Koji Dozono, Tsutomu Kawaguchi, Masakazu Toi
Oncologist. 2024 Mar; 29(3): e319–e329. Published online 2023 Nov 16. doi: 10.1093/oncolo/oyad301
PMCID:
PMC10911923
AbstractArticlePDF–2.3M
8.
Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
Alison D. Parisian, Susanna A. Barratt, Leslie Hodges-Gallagher, Fabian E. Ortega, Guadalupe Peña, Judevin Sapugay, Brandon Robello, Richard Sun, David Kulp, Gopinath S. Palanisamy, David C. Myles, Peter J. Kushner, Cyrus L. Harmon
Mol Cancer Ther. 2024 Mar 4; 23(3): 285–300. Published online 2023 Dec 15. doi: 10.1158/1535-7163.MCT-23-0351
PMCID:
PMC10911704
AbstractArticlePDF–4.3M
9.
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer
Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J. Cutts, Heena Shah, Laura Moretti, Lucy S. Kilburn, Hannah Johnson, Iain R. Macpherson, Alistair Ring, Judith M. Bliss, Yingwei Hou, Weiyi Toy, John A. Katzenellenbogen, Sarat Chandarlapaty, Nicholas C. Turner
Cancer Discov. 2024 Feb 8; 14(2): 274–289. Published online 2023 Nov 17. doi: 10.1158/2159-8290.CD-22-1387
PMCID:
PMC10850945
AbstractArticlePDF–16M
10.
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E. Martin, Bryanna L. Norden, Nicholas Chevalier, Allison M. Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi, Xin Yuan, Janice S. Kim, Haley Ellis, Alkistis Papatheodoridi, Hakan Gunaydin, Brian P. Danysh, Laxmi Parida, Ioannis Sanidas, Yongli Ji, Kayao Lau, Gerburg M. Wulf, Aditya Bardia, Laura M. Spring, Steven J. Isakoff, Jochen K. Lennerz, Kathryn Del Vecchio, Levi Pierce, Ermira Pazolli, Gad Getz, Ryan B. Corcoran, Dejan Juric
Cancer Discov. 2024 Feb 8; 14(2): 227–239. Published online 2023 Oct 31. doi: 10.1158/2159-8290.CD-23-0704
PMCID:
PMC10850944
AbstractArticlePDF–14M
11.
Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis
Lei Lei, Yuan Huang, Lei Shi, Weiwu Ye, Xianmei Lv, Lisha Ying, Xingfei Yu, Skye Hung-Chun Cheng, Yabing Zheng
Breast Cancer Res Treat. 2024; 203(3): 613–625. Published online 2023 Nov 4. doi: 10.1007/s10549-023-07138-0
PMCID:
PMC10806073
AbstractArticlePDF–5.1M
12.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
Cynthia X. Ma, Vera J. Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A. Marilyn Leitch, Gary W. Unzeitig, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard A. Gibbs, Mark A. Watson, Travis J. Dockter, Olwen Hahn, Joseph M. Guenther, Abigail Caudle, Erika Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Mothaffar F. Rimawi, Anna Weiss, Eric P. Winer, Kelly K. Hunt, Charles M. Perou, Matthew J. Ellis, Ann H. Partridge, Lisa A. Carey
JAMA Oncol. 2024 Mar; 10(3): 362–371. Published online 2024 Jan 18. doi: 10.1001/jamaoncol.2023.6038
PMCID:
PMC10797521
AbstractArticle
13.
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer
David W. Cescon, John Hilton, Serafin Morales Murilo, Rachel M. Layman, Timothy Pluard, Belinda Yeo, In Hae Park, Louise Provencher, Sung-Bae Kim, Young-Hyuck Im, Anastasia Wyce, Anu Shilpa Krishnatry, Kirsty Hicks, Qu Zhang, Olena Barbash, Ahmed Khaled, Thierry Horner, Arindam Dhar, Mafalda Oliveira, Joseph A. Sparano
Clin Cancer Res. 2024 Jan 17; 30(2): 334–343. Published online 2023 Nov 22. doi: 10.1158/1078-0432.CCR-23-0133
PMCID:
PMC10792358
AbstractArticlePDF–2.8M
14.
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
Sara M. Tolaney, Shom Goel, Jorge Nadal, Hannelore Denys, Manuel R. Borrego, Lacey M. Litchfield, Jiangang Liu, Adams K. Appiah, Yanyun Chen, Fabrice André
Clin Cancer Res. 2024 Jan 5; 30(1): 39–49. Published online 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-1209
PMCID:
PMC10767303
AbstractArticlePDF–442K
15.
The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
Xiewei Huang, Yushuai Yu, Shiping Luo, Wenfen Fu, Jie Zhang, Chuangui Song
BMC Cancer. 2024; 24: 21. Published online 2024 Jan 2. doi: 10.1186/s12885-023-11722-4
Correction in:
BMC Cancer. 2024; 24: 205.
PMCID:
PMC10763362
AbstractArticlePDF–1.4M
16.
17β-Estradiol-induced enhancement of estrogen receptor biosynthesis via MAPK pathway in mouse skeletal muscle myoblasts
J. Hatae, N. Takami, Hai Lin, Akira Honda, R. Inoue
J Physiol Sci. 2009 May; 59(3): 181–190. Published online 2009 Feb 25. doi: 10.1007/s12576-009-0023-0
PMCID:
PMC10717592
AbstractArticlePDF–440K
17.
A Gene Expression Biomarker Identifies Chemical Modulators of the Estrogen Receptor α (ERα) in a MCF-7 Microarray Compendium
John Rooney, Natalia Ryan, Jie Liu, René Houtman, Rinie van Beuningen, Jui-Hua Hsieh, Gregory Chang, Shiuan Chen, J. Christopher Corton
Chem Res Toxicol. Author manuscript; available in PMC 2023 Nov 28.
Published in final edited form as: Chem Res Toxicol. 2021 Feb 15; 34(2): 313–329. Published online 2021 Jan 6. doi: 10.1021/acs.chemrestox.0c00243
PMCID:
PMC10683854
AbstractArticlePDF–2.1M
18.
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
Yu-Chen Cheng, Shayna Stein, Agostina Nardone, Weihan Liu, Wen Ma, Gabriella Cohen, Cristina Guarducci, Thomas O. McDonald, Rinath Jeselsohn, Franziska Michor
Cancer Res Commun. 2023 Nov; 3(11): 2331–2344. Published online 2023 Nov 16. doi: 10.1158/2767-9764.CRC-23-0257
PMCID:
PMC10652811
AbstractArticlePDF–13M
19.
Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway
Konstantinos E. Siatis, Efstathia Giannopoulou, Dimitra Manou, Panagiotis Sarantis, Michalis V. Karamouzis, Sofia Raftopoulou, Konstantinos Fasseas, Fatimah Mohammed Alzahrani, Haralabos P. Kalofonos, Achilleas D. Theocharis
Am J Physiol Cell Physiol. 2023 Sep 1; 325(3): C708–C720. Published online 2023 Aug 14. doi: 10.1152/ajpcell.00199.2023
PMCID:
PMC10625825
AbstractArticle
20.
Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis
Yidong Ge, Jiabei Jin, Gun Chen, Jinyun Li, Meng Ye, Xiaofeng Jin
Cell Commun Signal. 2023; 21: 303. Published online 2023 Oct 30. doi: 10.1186/s12964-023-01342-7
PMCID:
PMC10614411
AbstractArticlePDF–6.8M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center